Idefirix (Imlifidase)

Imlifidase is a recombinant enzyme that cleaves human IgG at the lower hinge region. This enzymatic cleavage dismantles circulating IgG antibodies, including those directed against donor antigens, leading to a swift reduction in antibody titres and facilitating graft acceptance.

The dosing regimen for Idefirix is determined by the treating physician based on the patient’s clinical status, antibody levels, and transplant protocol. Specific dose amounts and infusion rates are individualized and should be prescribed by a qualified healthcare professional.

The safety of Idefirix in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a specialist.

To order Idefirix, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

The primary alternative for desensitization is therapeutic plasma exchange combined with intravenous immunoglobulin. Idefirix offers a rapid, single‑dose enzymatic reduction of IgG antibodies, whereas plasma exchange requires multiple sessions and may be less precise in antibody removal.

Idefirix must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Follow all cold‑chain handling procedures during transport and administration.

Idefirix is given as an intravenous infusion. The solution is administered by a qualified healthcare professional under controlled conditions, typically in a transplant centre or hospital setting, with appropriate monitoring for infusion‑related reactions.

Serious risks include anaphylaxis or severe allergic reactions, cytokine release syndrome, and thromboembolic events such as deep vein thrombosis. Immediate medical attention is required if any of these symptoms occur during or after infusion.

Idefirix should be avoided in patients with known hypersensitivity to Imlifidase or any component of the formulation, in those receiving live vaccines during treatment, and in individuals where the risk of severe immunosuppression outweighs the potential benefit, as determined by a transplant specialist.